Results 21 to 30 of about 77,990 (218)

The application of CAR-T cell therapy in hematological malignancies: advantages and challenges

open access: yesActa Pharmaceutica Sinica B, 2018
Chimeric antigen receptor T cell (CAR-T cell) therapy is a novel adoptive immunotherapy where T lymphocytes are engineered with synthetic receptors known as chimeric antigen receptors (CAR).
Zijun Zhao   +4 more
doaj   +1 more source

Conditionally Replicating Vectors Mobilize Chimeric Antigen Receptors against HIV

open access: yesMolecular Therapy: Methods & Clinical Development, 2020
Human immunodeficiency virus (HIV) is an attractive target for chimeric antigen receptor (CAR) therapy. CAR T cells have proved remarkably potent in targeted killing of cancer cells, and we surmised that CAR T cells could prove useful in eradicating HIV ...
Ryan Z. Urak   +8 more
doaj   +1 more source

Chimeric Antigen Receptors Expand the Repertoire of Antigenic Macromolecules for Cellular Immunity

open access: yesCells, 2021
T-cell therapies have made significant improvements in cancer treatment over the last decade. One cellular therapy utilizing T-cells involves the use of a chimeric MHC-independent antigen-recognition receptor, typically referred to as a chimeric antigen ...
John T. Keane, Avery D. Posey
doaj   +1 more source

Gene modification strategies for next-generation CAR T cells against solid cancers

open access: yesJournal of Hematology & Oncology, 2020
Immunotherapies have become the backbone of cancer treatment. Among them, chimeric antigen receptor (CAR) T cells have demonstrated great success in the treatment of hematological malignancies.
Yonggui Tian   +3 more
doaj   +1 more source

Post-translational covalent assembly of CAR and synNotch receptors for programmable antigen targeting

open access: yesNature Communications, 2023
Chimeric antigen receptors (CARs) and synthetic Notch (synNotch) receptors are engineered cell-surface receptors that sense a target antigen and respond by activating T cell receptor signaling or a customized gene program, respectively.
Elisa Ruffo   +10 more
doaj   +1 more source

Molecular Design, Optimization, and Genomic Integration of Chimeric B Cell Receptors in Murine B Cells

open access: yesFrontiers in Immunology, 2019
Immune cell therapies based on the integration of synthetic antigen receptors comprise a powerful strategy for the treatment of diverse diseases, most notably T cells engineered to express chimeric antigen receptors (CAR) for targeted cancer therapy.
Theresa Pesch   +9 more
doaj   +1 more source

Comparison of lentiviral and sleeping beauty mediated αβ T cell receptor gene transfer.

open access: yesPLoS ONE, 2013
Transfer of tumour antigen-specific receptors to T cells requires efficient delivery and integration of transgenes, and currently most clinical studies are using gamma retroviral or lentiviral systems.
Anne-Christine Field   +9 more
doaj   +1 more source

Cytokine Release Syndrome After Modified CAR-NK Therapy in an Advanced Non-small Cell Lung Cancer Patient: A Case Report

open access: yesCell Transplantation, 2022
Use of chimeric antigen receptors (CARs), as an immune cell therapy, has generated excellent clinical outcomes against hematologic tumors in recent years.
Xiaodi Zhang   +7 more
doaj   +1 more source

Organoids in pediatric cancer research

open access: yesFEBS Letters, EarlyView.
Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley   +1 more source

Cell surface interactome analysis identifies TSPAN4 as a negative regulator of PD‐L1 in melanoma

open access: yesMolecular Oncology, EarlyView.
Using cell surface proximity biotinylation, we identified tetraspanin TSPAN4 within the PD‐L1 interactome of melanoma cells. TSPAN4 negatively regulates PD‐L1 expression and lateral mobility by limiting its interaction with CMTM6 and promoting PD‐L1 degradation.
Guus A. Franken   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy